This episode of The Motley Fool's Market Checkup drills down on the day's hottest headlines and biggest market movers. Market Checkup gives a full examination of a shocking medical device takeover, a hot biotech that can't find an acquirer, a surprise announcement bringing a failed drug, and a big deal in gene sequencing.
In this video, health-care analyst David Williamson discusses Oncothyreon's surprise 20% pop today. Its lung cancer vaccine Stimuvax, now under the name tecemotide, is back from its phase 3 trial failure last year. Oncothyreon's partner, the German pharma Merck KGaA, saw enough in a subgroup to start a new phase 3 trial. Watch and find out why, despite the seemingly good news, investors should be cautious about these developments.
